Authors: Miravitlles, M Ros, F Cobos, A Kubin, R Tillotson, G

Citation: M. Miravitlles et al., The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis:A spanish physician and patient experience, INT J CL PR, 55(7), 2001, pp. 437-441

Authors: Iannini, PB Kubin, R Reiter, C Tillotson, G

Citation: Pb. Iannini et al., Reassuring safety profile of moxifloxacin, CLIN INF D, 32(7), 2001, pp. 1112-1114

Authors: Dalhoff, A Krasemann, C Wegener, S Tillotson, G

Citation: A. Dalhoff et al., Penicillin-resistant Streptococcus pneumoniae: Review of moxifloxacin activity, CLIN INF D, 32, 2001, pp. S22-S29

Authors: Krasemann, C Meyer, J Tillotson, G

Citation: C. Krasemann et al., Evaluation of the clinical microbiology profile of moxifloxacin, CLIN INF D, 32, 2001, pp. S51-S63

Authors: Mandell, LA Ball, P Tillotson, G

Citation: La. Mandell et al., Antimicrobial safety and tolerability: Differences and dilemmas, CLIN INF D, 32, 2001, pp. S72-S79

Authors: Ball, P Mandell, L Niki, Y Tillotson, G

Citation: P. Ball et al., Comparative tolerability of the newer fluoroquinolone antibacterials, DRUG SAFETY, 21(5), 1999, pp. 407-421